OTC denture cushion downclassifications sought by Mentholatum and Brimms.
This article was originally published in The Gray Sheet
Executive Summary
SOFT PLASTIC DENTURE CUSHION DOWNCLASSIFICATION: FDA SAFETY CONCERNS "are not applicable if cushions are only used temporarily until a dentist can be seen," Mentholatum argues in a July 26 petition requesting that FDA reclassify the over-the-counter devices from Class III to Class I. The petition was submitted in response to FDA's July 11 proposed call for premarket approval applications for OTC denture cushions or pads and repair kits ("The Gray Sheet" July 17, p. 15). The proposed rule covers all denture cushions/pads except those made of wax-impregnated cotton cloth and intended for one-day use, which are in Class I.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.